Ideas for ordinary days
The Everyday
Brief.
A little clarity.
A more manageable day.
Everyday life and news, connected to
peptide science through clear sources.
On your reading list
Thoughtful places to start.
-
IV NAD+ After a Heart Attack? What a New Hospital Trial Found
A 120-patient trial gave NAD+ by vein for a week after emergency stenting for a heart attack. Heart pumping was slightly better at 30 days, but repeat heart events at…
-
Vitamin B3 for Glaucoma? What the Nicotinamide Trials Show So Far
Small placebo-controlled trials found short-term gains in some retinal function tests when people with glaucoma took nicotinamide, an NAD+ precursor, but no trial has shown it slows glaucoma, high trial…
-
Gained Weight on a Newer HIV Pill? What Tesamorelin Data Show
Integrase-inhibitor HIV regimens are linked to weight gain. In a small subgroup of a year-long placebo trial, tesamorelin cut deep belly fat and liver fat in people on these drugs…
-
Kidney Disease and NAD+ Supplements: What the Trials Have Shown
In a small placebo-controlled trial in moderate kidney disease, nicotinamide riboside shifted blood chemistry but did not improve stamina, and kidney function held steady. Larger nicotinamide trials in kidney patients…
-
Stopping Egrifta: Deep Belly Fat Built Back Up in the Trials
In tesamorelin trials for HIV-related belly fat, visceral fat reaccumulated after patients switched to placebo, while those who stayed on it kept the drop for a year. Six months was…
-
TB Treatment and Vitamin D: The LL-37 Idea Fell Short in Trials
Vitamin D helps immune cells make LL-37, which attacks the TB germ in the lab. But in trials it did not prevent TB infection in more than 10,000 children, and…
-
An Old Hepatitis C Add-On: What the Thymosin Alpha-1 Trials Showed
Thymosin alpha-1 was tested for hepatitis C from the 1990s to 2012, alone and with interferon. The largest trial, 552 patients, found nearly the same cure rate with or without…
-
Can an NAD+ Booster Help a Weak Heart? A Small Placebo Trial Checked
In a 12-week placebo-controlled trial of 30 people with heart failure, nicotinamide riboside was well tolerated and roughly doubled blood NAD+, but walking distance, quality of life and heart pumping…
-
Is Vyleesi a Brain Drug? What a Placebo Brain-Scan Study Found
In a placebo-controlled crossover study of 31 women with low desire, a Vyleesi shot raised reported desire over the next day and changed brain responses to erotic videos. It explains…
-
Can Vitamin D Help Eczema by Raising the Skin Peptide LL-37?
Vitamin D can raise cathelicidin, the source of LL-37, in eczema skin, but a 101-child placebo trial found no change in LL-37 or severity. A winter trial in Mongolia did…
-
Fatty Liver Without HIV: A Year of Tesamorelin on Scans and Biopsies
A one-year placebo trial in 51 adults with obesity and fatty liver but no HIV posted results: liver fat on scans dipped with tesamorelin, but biopsy scores for inflammation and…
-
Will Adding Thymosin Alpha-1 to Entecavir Lower Liver Cancer Risk?
In 690 people with hepatitis B cirrhosis on entecavir, a year of added thymosin alpha-1 did not lower liver failure, liver cancer or death. Early lab gains in smaller trials…
How we work
Clear sources.
Useful everyday ideas.
We use AI assistance to prepare practical stories and link factual advice to its sources. Our editorial policy explains how we handle evidence, updates, and corrections.